Skip to content
Nonprofiteer
← CUREBOUND INC

Form 990 for tax year 2025

Filed by CUREBOUND INC.

Totals

Total revenue
$10,968,237
Total expenses
$14,851,654
Contributions and grants received
$7,968,991
Grants paid
$10,238,599
Program service revenue
$0
Investment income
$343,112
Other revenue
$2,656,134
Total assets, end of year
$11,857,815
Total liabilities, end of year
$2,822,688
Net assets or fund balances, end of year
$9,035,127
Program services expenses (Part IX)
$11,714,338
Management and general expenses
$1,688,385
Fundraising expenses
$1,448,931
Program service expenses (Part III)
$11,714,338

Program services were 78.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $5,455,260

  • 1f · All other contributions, gifts and grants

    $2,513,731

  • 1g · Noncash contributions included above

    $1,341,246

  • 3 · Investment income

    total $343,112 · excluded $343,112

  • 8a · Fundraising events: gross income

    $10,551,539

  • 8a · Fundraising events: contributions included on line 1c

    $5,455,260

  • 8b · Fundraising events: direct expenses

    $7,895,405

  • 8c · Net income from fundraising events

    total $2,656,134 · excluded $2,656,134

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $10,238,599 · program services $10,238,599

  • 5 · Compensation of officers, directors and key employees

    total $823,076 · program services $411,538 · management and general $205,769 · fundraising $205,769

  • 7 · Other salaries and wages

    total $1,703,341 · program services $643,557 · management and general $411,879 · fundraising $647,905

  • 9 · Other employee benefits

    total $199,643 · program services $43,199 · management and general $119,815 · fundraising $36,629

  • 10 · Payroll taxes

    total $185,996 · program services $72,811 · management and general $40,374 · fundraising $72,811

  • 11b · Fees: legal

    total $36,797 · management and general $36,797

  • 11c · Fees: accounting

    total $53,874 · management and general $53,874

  • 11g · Fees: other

    total $792,339 · program services $190,375 · management and general $253,094 · fundraising $348,870

  • 12 · Advertising and promotion

    total $69,355 · management and general $21,165 · fundraising $48,190

  • 13 · Office expenses

    total $35,802 · management and general $35,108 · fundraising $694

  • 14 · Information technology

    total $161,966 · program services $42,391 · management and general $119,575

  • 16 · Occupancy

    total $319,124 · program services $39,514 · management and general $211,017 · fundraising $68,593

  • 17 · Travel

    total $36,455 · management and general $36,455

  • 19 · Conferences, conventions and meetings

    total $52,322 · program services $11,175 · management and general $41,147

  • 22 · Depreciation, depletion and amortization

    total $18,291 · management and general $18,291

  • 23 · Insurance

    total $52,546 · management and general $52,546

  • 24a · Other expenses: DUES AND SUBSCRIPTION

    total $31,983 · program services $0 · management and general $30,983 · fundraising $1,000

  • 24b · Other expenses: FOOD AND BEVERAGE

    total $21,038 · program services $21,038 · management and general $0 · fundraising $0

  • 24c · Other expenses: PARTICIPANT DIRECT EXPE

    total $12,006 · program services $141 · management and general $0 · fundraising $11,865

  • 24d · Other expenses: EQUIPMENT AND RENTAL

    total $4,158 · program services $0 · management and general $0 · fundraising $4,158

  • 24e · All other expenses

    total $2,943 · management and general $496 · fundraising $2,447

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $1,238,683 · end of year $1,296,640

  • 2 · Savings and temporary cash investments

    beginning of year $8,297,334 · end of year $6,045,173

  • 3 · Pledges and grants receivable

    beginning of year $6,172,121 · end of year $3,734,254

  • 9 · Prepaid expenses and deferred charges

    beginning of year $338,409 · end of year $154,066

  • 14 · Intangible assets

    beginning of year $33,806 · end of year $15,515

  • 15 · Other assets

    beginning of year $360,530 · end of year $612,167

  • 17 · Accounts payable and accrued expenses

    beginning of year $270,843 · end of year $181,232

  • 18 · Grants payable

    beginning of year $1,012,360 · end of year $1,237,579

  • 19 · Deferred revenue

    beginning of year $1,875,372 · end of year $786,006

  • 25 · Other liabilities

    beginning of year $363,764 · end of year $617,871

  • 27 · Net assets without donor restrictions

    beginning of year $6,746,423 · end of year $5,374,341

  • 28 · Net assets with donor restrictions

    beginning of year $6,172,121 · end of year $3,660,786

Mission and programs · 2025

Mission

CUREBOUND'S MISSION IS TO ACCELERATE CANCER RESEARCH AND SAVE LIVES. WE RAISE AND INVEST STRATEGIC FUNDING FOR INNOVATIVE ADULT AND PEDIATRIC CANCER RESEARCH WITH ONE VISION: CURES IN OUR LIFETIME.

Activities or mission (Part I)

MOBILIZE SAN DIEGO TO ACCELERATE CURES FOR CANCER IN OUR LIFETIME.

  • CUREBOUND IS A COMMUNITY-POWERED CANCER RESEARCH ACCELERATOR WITH A UNIQUE FUNDING MODEL BUILT ON A CORE BELIEF THAT THE BEST IDEAS HAPPEN WHEN THE RIGHT PEOPLE WORK TOGETHER. WE UNITE TOP SCIENTISTS, PASSIONATE ADVOCATES, ENTREPRENEURS AND INVESTORS TO ADVANCE CANCER RESEARCH THAT HAS THE GREATEST OPPORTUNITY TO IMPROVE DETECTION, TREATMENT, AND SURVIVORSHIP. ALL CUREBOUND GRANTS DEMAND SCIENTIFIC COLLABORATION ACROSS INSTITUTIONS TO DRIVE RESULTS FOR PATIENTS WHO NEED IT NOW. THROUGH RIGOROUS REVIEW AND TRANSPARENCY, WE DIRECT EVERY INVESTMENT DOLLAR TOWARDS MEANINGFUL IMPACT. REPRESENTATIVE RESEARCH PARTNER INSTITUTIONS INCLUDE (BUT NOT LIMITED TO): UC SAN DIEGO MOORES CANCER CENTER, THE SALK INSTITUTE, SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, RADY CHILDREN'S HOSPITAL, SCRIPPS RESEARCH, AND LA JOLLA INSTITUTE OF IMMUNOLOGY.HEADQUARTERED IN SAN DIEGO, ONE OF THE NATION'S PREMIER HUBS FOR CANCER RESEARCH AND LIFE-SCIENCE INNOVATION, CUREBOUND CATALYZES COMPLEMENTARY STRENGTHS ACROSS BIOLOGY, TECHNOLOGY, DATA SCIENCE, AND CLINICAL NETWORKS TO ACCELERATE THE TRANSLATION OF DISCOVERY INTO CLINICAL IMPACT. CUREBOUND ALLOCATES AND ADMINISTERS RESEARCH FUNDING THROUGH FIVE GRANT MECHANISMS SPANNING DISCOVERY THROUGH CLINICAL TRANSLATION: DISCOVERY, TARGETED, CATALYST, EQUITY, CURE PRIZE. EACH OF THESE GRANT TYPES ALIGNS TO CUREBOUND'S OVERARCHING AND RESEARCH ROADMAP WITH CLEARLY DEFINED TIMELINES AND MEASURABLE MILESTONES THAT ARE TRACKED TO ACCELERATE PROGRESS.

    Expenses $11,714,338 · Grants $10,238,599

As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Donald B Kearns MD Mmm

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • John Hood PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Rob Singh

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Haeyoung Tang PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Fe Whitworth

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Dan Ryan

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Court Turner JD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Mark Cafferty

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Catriona Jamieson MD PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Rich Heyman PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Magda Marquet PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Julie Tafel Klaus

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Cheryl Am Anderson PhD MPH Ms

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Chris Tresse

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Larry Bloch

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Aaron Davis

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Bill Koman

    CHAIRPERSON

    Total calculated
    $0
    Hours/week
    1
  • Karen Hooper

    CHIEF OPERATING OFFICER

    Total calculated
    $325,985
    From this org
    $306,167
    From related orgs
    $0
    Other
    $19,818
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $220,500
    Bonus
    $85,667
    Other
    $0
    Deferred
    $11,043
    Nontaxable benefits
    $8,775
    Filer's total
    $325,985
  • Robin Toft

    SECRETARY

    Total calculated
    $0
    Hours/week
    1
  • Don Ankeny

    TREASURER

    Total calculated
    $0
    Hours/week
    1
  • Rick Valencia

    VICE-CHAIR

    Total calculated
    $0
    Hours/week
    1
  • Anne Marbarger

    CHIEF EXECUTIVE OFFICER

    Total calculated
    $497,091
    From this org
    $476,750
    From related orgs
    $0
    Other
    $20,341
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $323,750
    Bonus
    $153,000
    Other
    $0
    Deferred
    $13,470
    Nontaxable benefits
    $6,871
    Filer's total
    $497,091
  • Megan Ambrose

    CHIEF OF STAFF

    Total calculated
    $149,791
    From this org
    $142,448
    From related orgs
    $0
    Other
    $7,343
    Hours/week
    40
  • Heather Dean-Presnall

    SR. DIRECTOR, STEWARDSHIP

    Total calculated
    $163,962
    From this org
    $149,198
    From related orgs
    $0
    Other
    $14,764
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $130,729
    Bonus
    $18,469
    Other
    $0
    Deferred
    $5,989
    Nontaxable benefits
    $8,775
    Filer's total
    $163,962
  • Judith Polha

    DIRECTOR, RESEARCH & IMPACT

    Total calculated
    $142,639
    From this org
    $137,153
    From related orgs
    $0
    Other
    $5,486
    Hours/week
    40
  • Amy Myers

    SR. DIRECTOR, PHILANTHROPY

    Total calculated
    $149,239
    From this org
    $146,937
    From related orgs
    $0
    Other
    $2,302
    Hours/week
    40
  • Erik Hans Gordon

    DIRECTOR, MARKETING

    Total calculated
    $142,301
    From this org
    $134,195
    From related orgs
    $0
    Other
    $8,106
    Hours/week
    40

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Written employment contract
  • 3 · Approval by the board or compensation committee
  • 7 · Other non-fixed payments

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 7
ALL EMPLOYEES RECEIVED PERFORMANCE BONUSES.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

  • SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • BEKEN BIO INC

    $250,000

    SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • RESOLUTE SCIENCE INC

    $250,000

    SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • ILLUDENT INC

    $250,000

    SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

  • UNIVERSITY OF ARIZONA

    $100,000

    SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type
form_990
Tax year
2025
Filed
16 July 2026
IRS schema version
2025v4.2
Source object
202642059349300634

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.